Press Release

CDC approves Novavax; first protein-based COVID-19 vaccine

STATEWIDE (July 19, 2022) — Today, Centers for Disease Control and Prevention (CDC) gave final approval for use of the Novavax COVID-19 vaccine in adults aged 18 and older, as a two-dose primary COVID-19 vaccine series with the two doses separated by three weeks. This announcement followed the CDC’s Advisory Committee on Immunization Practices’ unanimous recommendation and FDA’s approval of emergency use authorization for the vaccine.